Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.

Article Details

Citation

Copy to clipboard

Hoveyda HR, Roy MO, Blanc S, Noel S, Salvino JM, Ator MA, Fraser G

Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):1991-6. doi: 10.1016/j.bmcl.2011.02.033. Epub 2011 Feb 13.

PubMed ID

21376585 [ View in PubMed

]

Abstract

A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca(2+) bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled human tachykinin NK(3) receptor (hNK3-R) is described. Preliminary profiling revealed poor plasma and metabolic stability for these structures in rodents. Further optimization efforts resulted in analogs with improved potency, stability, and pharmacokinetic properties as well as good brain permeability, for example, compounds 26 and 42. Unexpected cytotoxicity was observed in such N-Me pyrazole structures as compounds 41-42.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Osanetant	Neuromedin-K receptor	Ki (nM)	1.9	N/A	N/A	Details
Talnetant	Neuromedin-K receptor	Ki (nM)	7.4	N/A	N/A	Details